Search | Clinical Trials Finder

Conditions: Type 2 Diabetes Mellitus
Interventions: Canakinumab, Placebo, Metformin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more

Conditions: Osteoarthritis
Interventions: Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more

Conditions: HIV, Cardiovascular Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Priscilla Hsue, MD; Other
Eligibility: 40 Years to 59 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreatic Cancer
Interventions: Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: New York, New York

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions: Canakinumab (ACZ885); Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: PDR001, ACZ885, CJM112, TMT212, EGF816; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions: canakinumab, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more

Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Interventions: Canakinumab; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions: Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab; Drug
Lead sponsor: Jeffrey Curtis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more

Conditions: Gout
Interventions: Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more

Conditions: Acute Gout
Interventions: Canakinumab, Triamcinolone acetonide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more

Conditions: Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions: canakinumab (anti IL-1beta), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Hereditary Periodic Fevers
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Canakinumab, Metformin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: spartalizumab, LAG525, NIR178, capmatinib, MCS110, canakinumab; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: COVID-19, SARS-CoV 2
Interventions: Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Acute Gout
Interventions: Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 96
States / cities: Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 21
States / cities: Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Canakinumab, Pembrolizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more

Conditions: Acute Gouty Arthritis
Interventions: Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 69
States / cities: Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more

Search by objective public record fields.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Study of Canakinumab in Patients With Myelofibrosis

COVID-19 VaccinE Response in Rheumatology Patients

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients